| Summary of Company's Financial Data for Development and Commercialization of Pharmaceutical Products Segment |
The following table summarizes the Company’s financial data for its development and commercialization of pharmaceutical products segment:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
|
Net product sales |
|
$ |
3,752,142 |
|
|
$ |
2,551,366 |
|
|
$ |
6,832,300 |
|
|
$ |
4,286,856 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold |
|
|
(167,679 |
) |
|
|
(41,478 |
) |
|
|
(209,292 |
) |
|
|
(134,007 |
) |
|
Eversana profit sharing |
|
|
(3,188,997 |
) |
|
|
(2,168,661 |
) |
|
|
(5,807,132 |
) |
|
|
(3,643,922 |
) |
|
Employee expenses |
|
|
(631,795 |
) |
|
|
(561,171 |
) |
|
|
(1,269,894 |
) |
|
|
(1,257,973 |
) |
|
Professional fees |
|
|
(927,215 |
) |
|
|
(624,038 |
) |
|
|
(1,631,844 |
) |
|
|
(1,127,755 |
) |
|
Stock-based compensation |
|
|
(104,253 |
) |
|
|
(126,578 |
) |
|
|
(188,637 |
) |
|
|
(380,607 |
) |
|
Sales and marketing expenses |
|
|
(172,885 |
) |
|
|
(203,294 |
) |
|
|
(361,553 |
) |
|
|
(367,091 |
) |
|
Other operating expenses(1) |
|
|
(118,170 |
) |
|
|
(49,708 |
) |
|
|
(224,543 |
) |
|
|
(100,283 |
) |
|
Interest income |
|
|
112,534 |
|
|
|
81,001 |
|
|
|
231,386 |
|
|
|
127,059 |
|
|
Interest expense (non-cash) |
|
|
(124,658 |
) |
|
|
(124,657 |
) |
|
|
(247,945 |
) |
|
|
(249,315 |
) |
|
Total segment costs loss and net loss |
|
$ |
(1,570,976 |
) |
|
$ |
(1,267,218 |
) |
|
$ |
(2,877,154 |
) |
|
$ |
(2,847,038 |
) |
|
________________ (1) Includes ongoing product development costs, occupancy costs (including rent and utilities), administrative costs, travel and business taxes.
|